What Revelation Biosciences does

Revelation Biosciences is a clinical-stage biopharmaceutical company developing immunologic therapeutics based on a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist marketed as Gemini. The lead asset is an intravenously administered formulation designed to rebalance the innate immune response from a pro-inflammatory to a protective state, leveraging the 'trained immunity' mechanism. The company is advancing four indication programs on a single platform: GEM-AKI for acute kidney injury (the lead program targeting a Phase 2/3 adaptive design of approximately 300 patients with planned start in Q4 2026), GEM-CKD for chronic kidney disease, GEM-PSI for post-surgical infection prevention, and GEM-PBI for prevention of infection in severe burn patients. Core clinical evidence comes from a 40-patient Phase 1b PRIME study in Stage 3/4 CKD patients that showed statistically significant reductions in pro-inflammatory cytokines (p<0.01 to p<0.03) and restoration of immunocompetence in over 60% of previously non-responsive patients, with durable effect lasting up to 7 days after a single dose. The company secured an exclusive worldwide license from Vanderbilt University covering the GEM-PSI and GEM-PBI programs and is supported by a newly formed five-member Acute Kidney Injury Advisory Board of leading nephrologists and intensivists.

The business model is pre-commercial pharmaceutical development, with no revenue, no marketed products, and no commercial infrastructure. Future commercialization is expected to rely on direct hospital sales targeting ICU formularies, hospital pharmacies, and dialysis centers for the IV-administered therapeutic, with field sales teams engaging nephrologists, intensivists, and hospital procurement. To date, the company has funded operations through approximately $74 million raised across 13+ public offerings, private placements, and warrant exercises since 2020, with Roth Capital Partners serving as financial advisor for multiple transactions. Cash stood at $14.1 million as of March 31, 2026 (raised via a January 2026 warrant exercise of $11 million and a $6.7 million warrant inducement), with management projecting runway through Q1 2027 against a quarterly operating burn of approximately $3.2 million. The company is publicly traded on NASDAQ under the ticker REVB following a 2020 SPAC merger and has executed three reverse stock splits since January 2025 (1-for-16, 1-for-3, and 1-for-4) to maintain listing compliance.

Name

Revelation Biosciences

Legal name

Revelation Biosciences, Inc.

Website

https://revbiosciences.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Revelation Biosciences is a clinical-stage biopharmaceutical company developing Gemini, an IV-administered TLR4 agonist (PHAD®) that rebalances innate immunity, with lead programs in acute kidney injury and chronic kidney disease. Pre-revenue, publicly traded on NASDAQ (REVB), preparing for a pivotal Phase 2/3 AKI trial.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals (immunologic therapeutics)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Immunologic therapeutics
• TLR4 agonists
• Acute kidney injury
• Chronic kidney disease
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-commercial stage. The company is developing Gemini for multiple indications including acute kidney injury (GEM-AKI), chronic kidney disease (GEM-CKD), post-surgical infection prevention (GEM-PSI), and severe burn infection (GEM-PBI). No revenue currently as all programs are in clinical development stages.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Revelation Biosciences develops Gemini, an intravenously administered proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) that functions as a toll-like receptor 4 (TLR4) agonist. Gemini is being developed across multiple indication programs including GEM-AKI (acute kidney injury), GEM-CKD (chronic kidney disease), GEM-PSI (post-surgical infection prevention), and GEM-PBI (severe burn infection prevention), with the goal of reprogramming the innate immune system to deliver a durable attenuated response to inflammatory stress.

Product overview

Revelation Biosciences is a clinical-stage life sciences company developing proprietary pharmaceutical formulations based on phosphorylated hexaacyl disaccharide (PHAD) technology. The primary product is Gemini, an intravenously administered TLR4 agonist formulation. Gemini is the core platform being developed across multiple indication programs including GEM-AKI (acute kidney injury), GEM-CKD (chronic kidney disease), GEM-PSI (post-surgical infection), and GEM-PBI (post-burn infection). The company also has legacy pipeline candidates including REVTx-100, REVTx-200, REVTx-300, REVTx-99b, and REVDx-501 diagnostic. The product architecture is a single core formulation (Gemini) with multiple disease-specific indication programs, supported by GMP manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Gemini Gemini is an intravenously administered proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) that reduces damage associated with inflammation by reprogramming the innate immune system to respond to stress (trauma, infection) in an attenuated manner. It is a toll-like receptor 4 (TLR4) agonist with demonstrated durable effect up to 7 days from a single dose.
• GEM-AKI GEM-AKI is the indication program of Gemini being developed as a potential therapy for the treatment of acute kidney injury (AKI), redirecting the innate immune response from a pro-inflammatory state to an anti-inflammatory protective state. AKI affects over 20% of hospitalized patients and more than 50% of ICU patients, with no approved therapeutic treatments currently available.
• GEM-CKD GEM-CKD is the indication program of Gemini being developed as a potential therapy for the treatment of chronic kidney disease (CKD), aiming to slow or halt progressive destruction and scarring of organ tissue. CKD is caused by chronic inflammation and is a leading cause of death in the US.
• GEM-PSI GEM-PSI is the indication program of Gemini being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infection including post-surgical infection, developed through a license agreement with Vanderbilt University.
• GEM-PBI GEM-PBI is the indication program of Gemini being developed for the prevention of infection in severe burn patients requiring hospitalization, part of the patent family licensed from Vanderbilt University. Approximately 40,000 burn patients are admitted to US hospitals annually.

Quantifiable outcome

• Statistically significant reduction in elevated cytokines: p<0.01 at 2 hours, p<0.02 at 24 hours, p<0.03 at 168 hours post-dose
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Vanderbilt UniversitycoreOEM/ Whitelabel/ Licensing Partner · 29 April 2025Exclusive worldwide license agreement with Vanderbilt University for patent family covering use of Gemini for prevention of infection in severe burn patients and post-surgical infection. Vanderbilt researchers demonstrated in preclinical models that treatment post burn significantly reduces severity and duration of pseudomonas lung infection and reduces overall inflammation. The license enables GEM-PBI and GEM-PSI programs.
• AKI Advisory Board MemberscoreStrategic or Co-development PartnerAcute Kidney Injury Advisory Board comprising internationally recognized nephrologists and critical care physicians to guide Phase 2/3 clinical trial strategy. Members include Dr. Laurence Busse (Principal Investigator, Emory), Dr. Sean Bagshaw (University of Alberta), Dr. Stuart Goldstein (Cincinnati Children's), Dr. Javier Neyra (UAB), and Dr. Alexander Zarbock (University of Münster).

Scale indicators20 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• AM-Pharma: Clinical-stage biotech developing alkaline phosphatase for acute kidney injury; the most directly comparable competitor in AKI therapeutics with a similar pivotal-stage profile and similar hospital/critical care target market.
• Inotrem: Clinical-stage company developing a TLR4 pathway therapeutic (nangibotide) for septic shock and acute inflammatory conditions; directly comparable in targeting TLR4-driven innate immune dysregulation.
• Athersys: Clinical-stage cell therapy company that advanced MultiStem for AKI and other inflammatory indications; comparable as a small-cap clinical-stage biotech pursuing hospital-administered AKI therapy.
• Quark Pharmaceuticals: Clinical-stage RNA therapeutics company with programs in acute kidney injury and renal disease; comparable in targeting AKI with an investigational therapeutic in late preclinical/early clinical development.

Broad incumbents

• Bio-Techne: Established life-sciences tools and immunology reagents company with broad inflammation/innate immunity offerings; comparable as a large incumbent serving the TLR4 and inflammation research market that underpins Revelation's approach.
• Amgen: Global biopharmaceutical company with large inflammation/immunology portfolio (e.g., Otezla, Enbrel) and significant hospital channel presence; comparable as a broad incumbent in inflammation therapeutics that could compete in AKI if the space validates.
• AbbVie: Global biopharmaceutical company with a major immunology franchise (Humira, Skyrizi, Rinvoq); comparable as a broad incumbent in inflammation/immunology with the resources to enter adjacent indications like AKI.

Emerging players

• Soligenix: Late-clinical-stage biopharmaceutical company developing innate immunity therapeutics; comparable as a small clinical-stage peer in the immunomodulation/innate immunity space with a similar lean operating profile.
• Aldeyra Therapeutics: Clinical-stage company developing immunomodulators for inflammatory diseases; comparable as a small-cap clinical-stage peer pursuing novel inflammation mechanisms with similar regulatory engagement patterns.
• Chimerix: Clinical-stage biopharmaceutical company developing therapeutics for oncology and infectious/inflammatory diseases; comparable as a small clinical-stage peer in the broader inflammation/immunomodulation space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/RevBio1
• LinkedInlinkedin.com/company/revelation-biosciences-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds13 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revelation Biosciences